Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA?

Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA?

Can we extrapolate from what we learned about liraglutide in the LEADER trial to combination therapy that would employ a basal insulin in combination with this GLP-1 RA?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Derek LeRoith, MD, PhD

Derek LeRoith, MD, PhD

Professor of Medicine Director of Research in the Division of Endocrinology, Diabetes and Bone Diseases Mount Sinai School of Medicine New York, New York